论文部分内容阅读
目的:评估HSD3B1基因1245位点突变在去势抵抗型前列腺癌(castration-resistant prostate cancer,CRPC)发生中的作用。方法:回顾性分析2004年1月~2011年1月在我院行睾丸切除术的103例前列腺癌患者临床资料,其中HSD3B1基因1245位点突变18例。依据位点突变结果,将103例患者分为突变组及正常对照组,分别比较两组的PSA下降一半时间、CRPC形成率、CRPC形成时间、死亡率及生存时间等。结果:两组术前指标无异质性。突变组在CRPC形成率方面较对照组高,差异有统计学意义;但在PSA下降一半时间、CRPC形成时间、死亡率及生存时间等方面差异无统计学意义。结论:HSD3B1基因1245位点突变可提高CRPC形成率,但并没有缩短患者的生存时间及增加患者的死亡风险。HSD3B1基因1245位点突变是否会对CRPC将来的治疗带来改变,尚需进一步研究。
OBJECTIVE: To evaluate the role of site 1245 mutation in HSD3B1 gene in the development of castration-resistant prostate cancer (CRPC). Methods: The clinical data of 103 cases of prostate cancer undergoing orchiectomy in our hospital from January 2004 to January 2011 were retrospectively analyzed. Among them, 12 cases of HSD3B1 gene mutation were found in 12 cases. According to the results of site mutation, 103 patients were divided into the mutant group and the normal control group. The reduction of PSA, CRPC formation rate, CRPC formation time, mortality and survival time were compared between the two groups respectively. Results: The two groups of preoperative indicators without heterogeneity. The mutation group had higher CRPC formation rate than the control group, the difference was statistically significant; however, there was no significant difference in the time of CRPC formation, the death rate and the survival time in the half of PSA decline. Conclusion: The 1245 site mutation of HSD3B1 gene can improve the rate of CRPC formation, but it does not shorten the survival time of patients and increase the risk of death. HSD3B1 gene 1245 locus mutation whether CRPC will bring about future treatment, need further study.